A dedicated committee has been established to “push back” against the current down scheduling plan for CBD amid ongoing fears it will do little to make meaningful medicines more accessible for patients.
The policy group sub-committee on CBD rescheduling has been created by the Medicinal Cannabis Industry Association (MCIA) to ensure the plan does not backfire.
Under an application outlined by the Therapeutic Goods Administration (TGA), low-dose CBD – defined as 60mg per day for a maximum of 30 days – will be downgraded to schedule 3 of the Poisons Standard, making it available without prescription from pharmacies.
But there is concern it could be a political “quick fix” that creates confusion and provides little benefit to patients.
While a meeting of the Advisory Committee on Chemicals Scheduling (ACCS) and Advisory Committee on Medicines Scheduling (ACMS) has already taken place to discuss the down scheduling, the committee will continue to press home industry concern.
The move has already been described as a potential “red herring”, with several executives voicing concern over the requirements to prove efficacy at such low doses.
MCIA chairman Peter Crock suggested the TGA may have set an “arbitrary” maximum dosage because it is shown to be safe.
“But it might also have no effect,” he said. “It might be safe but are they just approving another high-cost supplement?